BRIEF published on 06/17/2026 at 15:22, 3 months ago Vanguard Discloses Position in Schroders plc Form 8.3 Takeover Code Schroders Plc Vanguard Group Shareholding Disclosure
BRIEF published on 06/17/2026 at 15:20, 3 months ago The Vanguard Group Discloses Position in Forward Industries Form 8.3 Irish Takeover Panel The Vanguard Group Shareholding Disclosure Forward Industries Inc.
BRIEF published on 06/17/2026 at 15:18, 3 months ago The Vanguard Group, Inc. Discloses Significant Shareholding in Beazley plc Form 8.3 Takeover Code Vanguard Group Stakeholding Beazley Plc
PRESS RELEASE published on 06/17/2026 at 15:17, 3 months ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc The Vanguard Group, Inc. discloses holding 2.57% stake in Schroders plc on 16 June 2026 per Form 8.3 under the Takeover Code Form 8.3 The Vanguard Group Takeover Code Schroders Plc Stake Disclosure
PRESS RELEASE published on 06/17/2026 at 15:15, 3 months ago Form 8.3 - The Vanguard Group, Inc.: Forward Industries Inc. The Vanguard Group, Inc. discloses a 2.11% interest in Forward Industries Inc. Ordinary Shares. No other parties involved. Dealings disclosed on 16 June 2026 Disclosure Vanguard Group Dealings Interests Forward Industries Inc.
PRESS RELEASE published on 06/17/2026 at 15:13, 3 months ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc The Vanguard Group, Inc. discloses 5.02% ownership of Beazley plc's 5p ordinary securities. Dealings disclosed on 16 June 2026 Securities Dealings The Vanguard Group Ownership Disclosure Beazley Plc 5p Ordinary
BRIEF published on 06/16/2026 at 15:10, 3 months 1 day ago The Vanguard Group, Inc. Discloses Stake in Tate & Lyle plc Form 8.3 Takeover Code Vanguard Group Shareholding Disclosure Tate & Lyle
BRIEF published on 06/16/2026 at 15:07, 3 months 1 day ago The Vanguard Group Discloses Position in Spire Healthcare Group Form 8.3 Takeover Code Securities Disclosure Vanguard Group Spire Healthcare
PRESS RELEASE published on 06/16/2026 at 15:05, 3 months 1 day ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc The Vanguard Group, Inc. discloses 4.74% stake in Tate & Lyle plc on 15 June 2026. Purchase of 92 securities at 5.67 GBP per unit disclosed The Vanguard Group, Inc. Stake Disclosure Securities Purchase Tate & Lyle Plc GBP 5.67
BRIEF published on 06/16/2026 at 15:03, 3 months 1 day ago The Vanguard Group Discloses Position in Schroders plc Takeover Code Schroders Plc Vanguard Group Stake Disclosure Equity Interests
Published on 09/18/2026 at 06:30, 5 hours 56 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 11 hours 31 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 12 hours 1 minute ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 14 hours 11 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/18/2026 at 12:00, 26 minutes ago BIRKENSTOCK OPENS A NEW STORE IN THE HEART OF BERLIN
Published on 09/18/2026 at 12:00, 26 minutes ago Warren Wise scans Siemens Healthineers: Sharp images for doctors, blurry ones for investors
Published on 09/18/2026 at 11:55, 31 minutes ago Xryma Plc Reports Steady H1 2026 Results While Positioning the Group for Its Next Phase of Growth
Published on 09/18/2026 at 11:50, 36 minutes ago German Companies Advance Investment Projects Worth More Than €600 Million in Latvia
Published on 09/18/2026 at 11:35, 51 minutes ago Huawei Unveils Upgraded Stellar AI Network to Power the Agentic World with Secure, Intelligent Connectivity
Published on 09/17/2026 at 17:40, 18 hours 46 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 18 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days 5 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
